for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Circassia Pharmaceuticals PLC

CIRCI.L

Latest Trade

19.50GBp

Change

0.10(+0.52%)

Volume

3,979,611

Today's Range

19.30

 - 

20.50

52 Week Range

13.25

 - 

59.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
19.40
Open
20.00
Volume
3,979,611
3M AVG Volume
81.63
Today's High
20.50
Today's Low
19.30
52 Week High
59.00
52 Week Low
13.25
Shares Out (MIL)
375.19
Market Cap (MIL)
73.16
Forward P/E
-2.25
Dividend (Yield %)
--

Next Event

Circassia Pharmaceuticals PLC Annual Shareholders Meeting

Latest Developments

More

Circassia Pharma 40% Revenue Growth To £27.9 Million In H1

Invesco Discloses 21.44% Stake In Circassia Pharmaceuticals As Of Sept 16 Vs Prior Stake Of 22.78% - Filing

Woodford Investment Management Discloses Less Than 5% Stake In Circassia Pharmaceuticals

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Circassia Pharmaceuticals PLC

Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates. Its next-generation immunotherapy is in Phase III testing for cat allergy. Its lead asthma treatment targets substitution of GlaxoSmithKline's (GSK's) Flixotide pMDI. It is developing therapies targeting direct substitution of Seretide pMDI and Serevent pMDI. The Company is also developing a range treatment, including a fixed dose triple combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.

Industry

Biotechnology & Drugs

Contact Info

Northbrook House, Robert Robinson Avenue

+44.1865.405560

http://www.circassia.com/

Executive Leadership

Ian Roy Johnson

Executive Chairman of the Board

Steven Charles Andrew Harris

Chief Executive Officer, Executive Director

Julien Cotta

Chief Financial Officer, Executive Director, Company Secretary

Jonathan Emms

Chief Operating Officer, Executive Director

Russell Cummings

Non-Executive Director

Key Stats

2.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (GBp)

2016

-20.000

2017

-11.000

2018

-7.520

2019(E)

-8.650
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.53
Price To Book (MRQ)
0.67
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
20.40
LT Debt To Equity (MRQ)
19.67
Return on Investment (TTM)
-18.28
Return on Equity (TTM)
-15.00

Latest News

Latest News

Woodford discloses less than 5% stake in Circassia Pharmaceuticals: filing

British asset manager Woodford Investment Management Ltd disclosed a less than 5% stake in Circassia Pharmaceuticals Plc <CIRCI.L> as of Sept. 13, a filing showed on Monday.

AstraZeneca raises stake in respiratory partner Circassia

AstraZeneca <AZN.L> is paying up to $45 million to increase its stake in Circassia <CIRCI.L>, backing a company seeking to bounce back from the failure of its allergy drugs by switching all of its focus to respiratory medicines.

AstraZeneca to raise stake in Circassia to up to 19.9 pct

British pharmaceutical company AstraZeneca said it would subscribe for more shares in Circassia by injecting cash into the respiratory drug specialist to take its stake to a maximum of 19.9 percent from 14.2 percent.

BRIEF-Circassia Pharmaceuticals Names Three Non-Executive Directors ​

* JO LE COUILLIARD IS APPOINTED AS A NON-EXECUTIVE DIRECTOR WITH IMMEDIATE EFFECT.

BRIEF-Circassia Pharmaceuticals Gets Innovative Tech Contract From Vizient​

* RECEIVED A MULTI-YEAR INNOVATIVE TECHNOLOGY CONTRACT FOR ITS NIOX VERO® ASTHMA MANAGEMENT PRODUCTS FROM VIZIENT, INC Source text for Eikon: Further company coverage:

BRIEF-Circassia Pharmaceuticals Says ‍Tudorza Meets Primary Endpoints In Ascent Study​

* TUDORZA® SUCCESSFULLY MET BOTH PRIMARY ENDPOINTS IN ASCENT PHASE IV STUDY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Circassia Pharmaceuticals says H1 revenues up 65 pct to 18.3 mln pounds

* H1 REVENUE OF 18.3 MILLION STG VERSUS 11.1 MILLION STG YEAR AGO

BRIEF-Circassia Pharma says Duaklir improves lung function in COPD patients

* Announces duaklir® successfully met primary endpoints in amplify phase iii study in chronic obstructive pulmonary disease

BRIEF-Circassia Pharmaceuticals fy revenues increased to 23.1 mln stg

* FY revenues increased to £23.1 million (2015: £10.8 million)

Circassia gives up on allergy after house dust mite study fails

Britain's Circassia Pharmaceuticals is throwing in the towel on allergy investment after a second high-profile clinical trial flop, focusing instead on building a broader respiratory business.

BRIEF-Circassia to secure certain U.S. commercial rights to Tudorza, Duaklir from AstraZeneca

* Proposed collaboration and securing of certain U.S. Commercial rights to Tudorza And Duaklir from Astrazeneca

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up